Los Angeles Capital Management LLC Sells 19,081 Shares of United Therapeutics Corporation $UTHR

Los Angeles Capital Management LLC reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 31.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,510 shares of the biotechnology company’s stock after selling 19,081 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.10% of United Therapeutics worth $19,280,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Havemeyer Place LP bought a new position in shares of United Therapeutics in the fourth quarter valued at $2,189,000. Vestcor Inc grew its stake in shares of United Therapeutics by 12.3% in the fourth quarter. Vestcor Inc now owns 3,433 shares of the biotechnology company’s stock valued at $1,673,000 after buying an additional 377 shares in the last quarter. Pinebridge Investments LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at $1,943,000. PBU The Pension Fund of Early Childhood & Youth Educators bought a new position in shares of United Therapeutics in the fourth quarter valued at $4,803,000. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in shares of United Therapeutics by 1.4% in the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 27,880 shares of the biotechnology company’s stock valued at $13,585,000 after buying an additional 380 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

UTHR stock opened at $549.87 on Monday. The company has a fifty day moving average price of $568.23 and a two-hundred day moving average price of $519.16. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market cap of $23.34 billion, a price-to-earnings ratio of 20.30, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period last year, the firm earned $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 614,543 shares of company stock worth $346,728,395 over the last three months. Insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Finally, Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.